GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for TRANSCEND

TRANSCEND

Official Title

Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.

Status

Completed

Overview

To determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of CV death, MI, stroke or hospitalization for CHF in patients who are intolerant to ACE-I.

Study Design

Parallel group design.

Primary Endpoint

Cardiovascular death Non-fatal myocardial infarction Non-fatal stroke Hospitalization for congestive heart failure. Secondary endpoints: Newly diagnosed CHF. CV revascularization procedures. Newly diagnosed diabetes. Cognitive decline (adjudication done by a special committee), new onset of atrial fibrillation, nephropathy. All primary and secondary endpoints were adjudicated.

Number of Patients

5926

Number of Sites

733

Number of Countries

40

Study Period

2001–2008

Principal Investigator

Salim Yusuf

Program Manager

Barbara Ramos

Research Coordinator

Ingrid Copland

Key Publications

  • The Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.
  • Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K, on behalf of the ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients with high cardiovascular risk. Circulation 2007;115:1371-1375.